Johnson & Johnson

Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
  • TickerJNJ
  • ISINUS4781601046
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

JNJ Johnson & Johns... (Health Care)

Moody's: J&J opioid settlement adds financial leverage but reduces unc...

Announcement: Moody's: J&J opioid settlement adds financial leverage but reduces uncertainty. Global Credit Research- 23 Jul 2021. New York, July 23, 2021-- Moody's Investors Service commented that the announcement that Johnson& Johnson has entered a national opioid settlement agreement is credit negative.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson - April 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

JNJ Johnson & Johns... (Health Care)

Moody's: Denial of J&J's talc verdict appeal highlights litigation exp...

Announcement: Moody's: Denial of J&J's talc verdict appeal highlights litigation exposures. Global Credit Research- 02 Jun 2021. New York, June 02, 2021-- Moody's Investors Service, commented that the recent decision by the US Supreme Court to deny hearing a petition related to a Missouri talc lawsuit highlights material, unresolved litigation exposures for Johnson& Johnson.

JNJ Johnson & Johns... (Health Care)

Johnson & Johnson: Denial of talc verdict appeal highlights litigation...

The $2.5 billion payment will reduce cash on hand, but talc litigation is in early stages and financial flexibility is strong

Valens Research
  • Valens Research
JNJ Johnson & Johns... (Health Care)

JNJ - Embedded Expectations Analysis - 2021 05 21

Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investments Specifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the pote...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch